Synergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinoma

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Jiang, Minghong ^a   Liu, Zheng ^a   Xiang, Yang ^a   Ma, Hong ^a   Liu, Shilian ^a   Liu, Yanxin ^a   Zheng, Dexian ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ENHANCED GREEN FLUORESCENT PROTEIN; PARVOVIRUS VECTOR; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ANTINEOPLASTIC AGENT; GREEN FLUORESCENT PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; GENE EXPRESSION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; FLUORESCENCE MICROSCOPY; GENE THERAPY; GENE VECTOR; GENETICS; HEAD AND NECK TUMOR; METABOLISM; METHODOLOGY; MULTIMODALITY CANCER THERAPY; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; COMBINED MODALITY THERAPY; DEPENDOVIRUS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROSCOPY, FLUORESCENCE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79551528437     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-54     Document Type: Article

References (36)

1. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med 2001, 345(26):1890-1900. 10.1056/NEJMra001375, 11756581.
2. Catimel G. Head and neck cancer: guidelines for chemotherapy. Drugs 1996, 51(1):73-88. 10.2165/00003495-199651010-00006, 8741233.
3. Boulikas T, Vougiouka M. Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review). Oncol Rep 2004, 11(3):559-595.
4. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005, 23(34):8646-8654. 10.1200/JCO.2005.02.4646, 16314626.
5. Kojima H, Iida M, Yaguchi Y, Suzuki R, Hayashi N, Moriyama H, Manome Y. Enhancement of Cisplatin sensitivity in squamous cell carcinoma of the head and neck transfected with a survivin antisense gene. Arch Otolaryngol Head Neck Surg 2006, 132(6):682-685. 10.1001/archotol.132.6.682, 16785416.
6. Shamimi-Noori S, Yeow WS, Ziauddin MF, Xin H, Tran TL, Xie J, Loehfelm A, Patel P, Yang J, Schrump DS, et al. Cisplatin enhances the antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand gene therapy via recruitment of the mitochondria-dependent death signaling pathway. Cancer Gene Ther 2008, 15(6):356-370. 10.1038/sj.cgt.7701120, 18309355.
7. Mandel RJ, Manfredsson FP, Foust KD, Rising A, Reimsnider S, Nash K, Burger C. Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders. Mol Ther 2006, 13(3):463-483. 10.1016/j.ymthe.2005.11.009, 16412695.
8. Carter BJ. Adeno-associated virus vectors. Curr Opin Biotechnol 1992, 3(5):533-539. 10.1016/0958-1669(92)90082-T, 1369403.
9. Wagner JA, Reynolds T, Moran ML, Moss RB, Wine JJ, Flotte TR, Gardner P. Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus. Lancet 1998, 351(9117):1702-1703. 10.1016/S0140-6736(05)77740-0, 9734891.
10. Muramatsu S, Fujimoto K, Ikeguchi K, Shizuma N, Kawasaki K, Ono F, Shen Y, Wang L, Mizukami H, Kume A, et al. Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Hum Gene Ther 2002, 13(3):345-354. 10.1089/10430340252792486, 11860702.
11. Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A, Glader B, Chew AJ, Tai SJ, Herzog RW, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000, 24(3):257-261. 10.1038/73464, 10700178.
12. Kanazawa T, Urabe M, Mizukami H, Okada T, Kume A, Nishino H, Monahan J, Kitamura K, Ichimura K, Ozawa K. Gamma-rays enhance rAAV-mediated transgene expression and cytocidal effect of AAV-HSVtk/ganciclovir on cancer cells. Cancer Gene Ther 2001, 8(2):99-106. 10.1038/sj.cgt.7700282, 11263531.
13. Fisher KJ, Gao GP, Weitzman MD, DeMatteo R, Burda JF, Wilson JM. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol 1996, 70(1):520-532. 189840, 8523565.
14. Ferrari FK, Samulski T, Shenk T, Samulski RJ. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol 1996, 70(5):3227-3234. 190186, 8627803.
15. Alexander IE, Russell DW, Miller AD. DNA-damaging agents greatly increase the transduction of nondividing cells by adeno-associated virus vectors. J Virol 1994, 68(12):8282-8287. 237296, 7966621.
16. Yan Z, Zak R, Zhang Y, Ding W, Godwin S, Munson K, Peluso R, Engelhardt JF. Distinct classes of proteasome-modulating agents cooperatively augment recombinant adeno-associated virus type 2 and type 5-mediated transduction from the apical surfaces of human airway epithelia. J Virol 2004, 78(6):2863-2874. 10.1128/JVI.78.6.2863-2874.2004, 353734, 14990705.
17. Zhang T, Hu J, Ding W, Wang X. Doxorubicin augments rAAV-2 transduction in rat neuronal cells. Neurochem Int 2009, 55(7):521-528. 10.1016/j.neuint.2009.05.005, 19450628.
18. Chen CA, Lo CK, Lin BL, Sibley E, Tang SC. Application of doxorubicin-induced rAAV2-p53 gene delivery in combined chemotherapy and gene therapy for hepatocellular carcinoma. Cancer Biol Ther 2008, 7(2):303-309. 10.4161/cbt.7.2.5333, 18059187.
19. Kanazawa T, Mizukami H, Okada T, Hanazono Y, Kume A, Nishino H, Takeuchi K, Kitamura K, Ichimura K, Ozawa K. Suicide gene therapy using AAV-HSVtk/ganciclovir in combination with irradiation results in regression of human head and neck cancer xenografts in nude mice. Gene Ther 2003, 10(1):51-58. 10.1038/sj.gt.3301837, 12525837.
20. Takahara PM, Rosenzweig AC, Frederick CA, Lippard SJ. Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin. Nature 1995, 377(6550):649-652. 10.1038/377649a0, 7566180.
21. Cohen SM, Lippard SJ. Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol 2001, 67:93-130. full_text, 11525387.
22. Zhang XD, Nguyen T, Thomas WD, Sanders JE, Hersey P. Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett 2000, 482(3):193-199. 10.1016/S0014-5793(00)02042-1, 11024459.
23. Mohr A, Henderson G, Dudus L, Herr I, Kuerschner T, Debatin KM, Weiher H, Fisher KJ, Zwacka RM. AAV-encoded expression of TRAIL in experimental human colorectal cancer leads to tumor regression. Gene Ther 2004, 11(6):534-543. 10.1038/sj.gt.3302154, 14999225.
24. Ma H, Liu Y, Liu S, Kung HF, Sun X, Zheng D, Xu R. Recombinant adeno-associated virus-mediated TRAIL gene therapy suppresses liver metastatic tumors. Int J Cancer 2005, 116(2):314-321. 10.1002/ijc.20982, 15800912.
25. Ma H, Liu Y, Liu S, Xu R, Zheng D. Oral adeno-associated virus-sTRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice. Hepatology 2005, 42(6):1355-1363. 10.1002/hep.20918, 16317690.
26. Shi J, Zheng D, Liu Y, Sham MH, Tam P, Farzaneh F, Xu R. Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice. Cancer Res 2005, 65(5):1687-1692. 10.1158/0008-5472.CAN-04-2749, 15753363.
27. Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998, 72(2):1438-1445. 124624, 9445046.
28. Russell DW, Alexander IE, Miller AD. DNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors. Proc Natl Acad Sci USA 1995, 92(12):5719-5723. 10.1073/pnas.92.12.5719, 41768, 7777575.
29. El-Deiry WS. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling. Cell Death Differ 2001, 8(11):1066-1075. 10.1038/sj.cdd.4400943, 11687885.
30. Reddy RM, Tsai WS, Ziauddin MF, Zuo J, Cole GW, Maxhimer JB, Fang B, Schrump DS, Nguyen DM. Cisplatin enhances apoptosis induced by a tumor-selective adenovirus expressing tumor necrosis factor-related apoptosis-inducing ligand. J Thorac Cardiovasc Surg 2004, 128(6):883-891. 10.1016/S0022-5223(04)00982-1, 15573073.
31. Siervo-Sassi RR, Marrangoni AM, Feng X, Naoumova N, Winans M, Edwards RP, Lokshin A. Physiological and molecular effects of Apo2L/TRAIL and cisplatin in ovarian carcinoma cell lines. Cancer Lett 2003, 190(1):61-72. 10.1016/S0304-3835(02)00579-7, 12536078.
32. Woods DC, Alvarez C, Johnson AL. Cisplatin-mediated sensitivity to TRAIL-induced cell death in human granulosa tumor cells. Gynecol Oncol 2008, 108(3):632-640. 10.1016/j.ygyno.2007.11.034, 18191995.
33. Kondo K, Yamasaki S, Inoue N, Sugie T, Teratani N, Kan T, Shimada Y. Prospective antitumor effects of the combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and cisplatin against esophageal squamous cell carcinoma. Surg Today 2006, 36(11):966-974. 10.1007/s00595-006-3295-5, 17072716.
34. Liu P, Mao H, Hou P. Synergistic antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand combined with cisplatin in ovarian carcinoma cell lines in vitro and in vivo. Int J Gynecol Cancer 2006, 16(2):538-548. 10.1111/j.1525-1438.2006.00507.x, 16681723.
35. Duverger V, Sartorius U, Klein-Bauernschmitt P, Krammer PH, Schlehofer JR. Enhancement of cisplatin-induced apoptosis by infection with adeno-associated virus type 2. Int J Cancer 2002, 97(5):706-712. 10.1002/ijc.10077, 11807802.
36. Yoo J, Choi S, Hwang KS, Cho WK, Jung CR, Kwon ST, Im DS. Adeno-associated virus-mediated gene transfer of a secreted form of TRAIL inhibits tumor growth and occurrence in an experimental tumor model. J Gene Med 2006, 8(2):163-174. 10.1002/jgm.832, 16144019.